Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Ocular Pain-Pipeline Review, H1 2015

Ocular Pain-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Ocular Pain-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ocular Pain-Pipeline Review, H1 2015', provides an overview of the Ocular Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Ocular Pain

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Ocular Pain and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Ocular Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Ocular Pain pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Ocular Pain

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Ocular Pain Overview 7

Therapeutics Development 8

Pipeline Products for Ocular Pain-Overview 8

Pipeline Products for Ocular Pain-Comparative Analysis 9

Ocular Pain-Therapeutics under Development by Companies 10

Ocular Pain-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Ocular Pain-Products under Development by Companies 14

Ocular Pain-Companies Involved in Therapeutics Development 15

Auven Therapeutics Management L.L.L.P 15

Bayer AG 16

InSite Vision Incorporated 17

Kala Pharmaceuticals, Inc. 18

NicOx S.A. 19

Reata Pharmaceuticals, Inc. 20

Sylentis S.A. 21

Valeant Pharmaceuticals International, Inc. 22

Ocular Pain-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by 28

Assessment by Molecule Type 30

Drug Profiles 32

fluticasone propionate-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

ISV-303-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ketorolac tromethamine-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

loteprednol etabonate-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

loteprednol etabonate next generation-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

mapracorat-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

NT-71-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

NT-72-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

RTA-408-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

RX-10045-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

SYL-1001-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Ocular Pain-Recent Pipeline Updates 48

Ocular Pain-Dormant Projects 55

Ocular Pain-Product Development Milestones 56

Featured News & Press Releases 56

Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 56

May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 56

Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite 57

Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 57

Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 58

Nov 29, 2012: InSite Vision Completes Patient Enrollment In Phase III Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 58

Jul 31, 2012: InSite Vision Initiates First Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 59

Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 60

Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 61

Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate 62

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64

List of Tables

Number of Products under Development for Ocular Pain, H1 2015 8

Number of Products under Development for Ocular Pain-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Ocular Pain-Pipeline by Auven Therapeutics Management L.L.L.P, H1 2015 15

Ocular Pain-Pipeline by Bayer AG, H1 2015 16

Ocular Pain-Pipeline by InSite Vision Incorporated, H1 2015 17

Ocular Pain-Pipeline by Kala Pharmaceuticals, Inc., H1 2015 18

Ocular Pain-Pipeline by NicOx S.A., H1 2015 19

Ocular Pain-Pipeline by Reata Pharmaceuticals, Inc., H1 2015 20

Ocular Pain-Pipeline by Sylentis S.A., H1 2015 21

Ocular Pain-Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 22

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Stage and Target, H1 2015 25

Number of Products by Stage and Mechanism of Action, H1 2015 27

Number of Products by Stage and Route of Administration, H1 2015 29

Number of Products by Stage and Molecule Type, H1 2015 31

Ocular Pain Therapeutics-Recent Pipeline Updates, H1 2015 48

Ocular Pain-Dormant Projects, H1 2015 55

List of Figures

Number of Products under Development for Ocular Pain, H1 2015 8

Number of Products under Development for Ocular Pain-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 12

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Top 10 Targets, H1 2015 24

Number of Products by Stage and Top 10 Targets, H1 2015 25

Number of Products by Top 10 Mechanism of Actions, H1 2015 26

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Top 10 Routes of Administration, H1 2015 28

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 29

Number of Products by Top 10 Molecule Types, H1 2015 30

Number of Products by Stage and Top 10 Molecule Types, H1 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Auven Therapeutics Management L.L.L.P

Bayer AG

InSite Vision Incorporated

Kala Pharmaceuticals, Inc.

NicOx S.A.

Reata Pharmaceuticals, Inc.

Sylentis S.A.

Valeant Pharmaceuticals International, Inc.

Ocular Pain Therapeutic Products under Development, Key Players in Ocular Pain Therapeutics, Ocular Pain Pipeline Overview, Ocular Pain Pipeline, Ocular Pain Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com